Drug intelligence / Profile preview

KD303

Development stage: Preclinical
Lead developer: Kwang Dong Pharmaceutical
Modality: Small Molecules

Overview

**KD303** is a Kwang Dong Pharmaceutical development candidate for **circulatory system disorders**. The company pipeline identifies the program as being in formulation research; its molecular identity, pharmacologic target, mechanism of action, dosage form, route of administration, and specific cardiovascular indication have not been publicly disclosed. A third-party drug intelligence record characterizes KD303 as a preclinical small-molecule program. ([synapse.patsnap.com](https://synapse.patsnap.com/drug/fe20f8fc132e494381e83127c6b38113))

Beyond the preview

Go deeper on KD303.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KD303.

Explore the full profile